Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia

1. Sign the informed consent and be willing and able to comply with the visit, treatment regimen, laboratory examination and other requirements of the study as stipulated in the trial flow chart;

2. A definite diagnosis of B-cell Lymphocyte Leukemia, which meets any of the following criteria: Relapsed : a) relapsed within 12 months after first remission;Refractory: a) no remission after six weeks of induction therapy or no remission after two courses of induction therapy; b) relapsedafter CR for 2 or more times; c) The first relapse after chemotherapy and no remission after at least one salvage treatment; c) relapsed after hematopoietic stem cell transplantation;

3. ECOG Scores: 0~2

4. CD19 positive and CD22 positive were detected by immunohistochemistry or flow cytometry;

5. Estimated survival time>3 months;

6. Peripheral blood mononuclear immune cells must be collected at least 2 weeks after the last radiotherapy or systemic treatment.

7. For patients with only extramedullary recurrence of B-ALL, there must be at least one assessable lesion.

1. Serious cardiac insufficiency；

2. Has a history of severe pulmonary function damaging;

3. Presence of other malignant tumors.

4. Presence of active fungal, bacterial, viral, or other infection requiring IV antibiotics for management.

5. Presence of other severe autoimmune diseases or immunodeficiency disease;

6. Patients with active hepatitis B or hepatitis C([HBVDNA+]or [HCVRNA+]);

7. Known positive serology for human immunodeficiency virus (HIV) or syphilis。

8. Has a history of serious allergies on biological products (including antibiotics);

9. Female patients who are under pregnancy and/or lactation, or planing on pregnancy for the next 12 months.

10. Any other situations that the researchers believe will affect the results of the study.